Nasser Hanna, M.D.

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Nasser Hanna, M.D. sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 5 completed early-phase tilt upper quartile by trial count

Nasser Hanna, M.D.: 8 sponsored US clinical trials, none currently recruiting.

Nasser Hanna, M.D. sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 1 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Esophageal Cancer, with 1 trials.

Upper-quartile sponsor footprint

Nasser Hanna, M.D. sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

TERMINATED Phase 2

Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor

NCT03041181
TERMINATED Phase 2

Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors

NCT02499952
COMPLETED Phase 2

Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC

NCT02343952
TERMINATED Phase 1

Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer

NCT00417248
COMPLETED Phase 2

Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer

NCT00367601
COMPLETED Phase 2

Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas

NCT00319735
COMPLETED Phase 1

Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer

NCT00216203
COMPLETED Phase 3

Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer

NCT00216125

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 5
Phase 3 1

Therapeutic Areas

Esophageal Cancer 1
Non-Small Cell Lung Cancer 1

How the Nasser Hanna, M.D. early-phase archive is shaped

8 indexed studies, none listed as recruiting (0% open); 5 completed (63%).

Phase mix: 1 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Esophageal Cancer (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Nasser Hanna, M.D.: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Nasser Hanna, M.D. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Nasser Hanna, M.D.AB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
Nasser Hanna, M.D. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Nasser Hanna, M.D. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Nasser Hanna, M.D. page

8 registered trials is a research-attention snapshot, not an endorsement of Nasser Hanna, M.D. or any single study.

  • None of Nasser Hanna, M.D.'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Esophageal Cancer is the condition Nasser Hanna, M.D. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Esophageal Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Nasser Hanna, M.D. pipeline card: 8 registered trials from official public datasets.Report a data error.